Cherry put a soft credit check inside 60,000 dentists' offices.

Walk into any decent dental office in America today. Behind the receptionist's monitor, past the loyalty card holder and the bowl of sugar-free mints, there is a small white tablet. A patient just finished a consult for crowns. The number is $6,400. The patient hesitates. The receptionist taps the tablet. Sixty seconds later the patient walks out with crowns scheduled and a payment plan. The practice has the money - all of it - by Friday. That tablet, more often than not, is running Cherry.

Cherry is the fintech that nobody at a San Francisco dinner party can quite describe, because Cherry's customer is not at the dinner party. Cherry's customer is the office manager at a periodontist in Tulsa. Cherry's customer is the medspa owner in Tampa who would like to stop chasing $400 unpaid balances. Cherry's customer is - increasingly - the orthodontist, the dermatologist, the veterinarian, the optometrist, the audiologist, and the plastic surgeon. More than 60,000 of them have signed up. Most of their patients have never heard the name.

01The problem they saw

American healthcare has a peculiar billing pathology. The procedure costs four figures. The patient can afford payments, not the lump sum. The provider can offer a plan, but doing so means becoming, against their will, a lender - chasing balances, eating defaults, hiring a billing clerk who used to be a hygienist. For thirty years the workaround was CareCredit, a Synchrony product that did the job and looked the part - it looked, specifically, like a 1990s credit card application taped to the wall.

The other workaround was worse. Half of all elective treatment plans simply got walked away from. The patient went home, intended to come back, did not. The dentist absorbed the lost case. The patient absorbed the toothache. Neither was happy. Both blamed money.

The opportunity, then, was hiding in a place nobody at a fintech conference wanted to look - the back office of a Tuesday-morning dentist. It was unglamorous. It was paper-based. It was also, depending on whose figures you trust, a tens-of-billions-of-dollars annual flow of underserved transactions.

02The founders' bet

In 2019, Felix Steinmeyer - a former investment banker from Germany - and Charles Mourani - a French engineer who had built systems at a series of Bay Area companies - made a bet that looked, at the time, slightly perverse. The bet was this: that the most interesting consumer fintech opportunity in the United States was not a debit card with a clever onboarding flow. It was not a robo-advisor for Gen Z. It was the underwriting that would happen in the four minutes between a treatment consultation and a checkout.

They were not wrong. They were also not the only ones to notice. Affirm was looking at the healthcare BNPL category. Klarna was looking. Sunbit had launched a competing product. CareCredit, the incumbent, had decades of distribution. Cherry's bet was that distribution would matter more than balance sheet - and that if you built the cleanest, fastest, most provider-friendly merchant tool, the providers would do the selling for you.

Fig. 1 - Numbers Cherry would like you to remember, in roughly the order they appear on a sales call.

03The product, in plain English

A patient sits in the consult chair. The treatment estimate is $4,800. The office staff sends the patient a text or a QR code. The patient enters a name, an income, a date of birth. Cherry runs a soft credit pull - no score impact, no scary letters from the bureau. Within a minute the patient sees a menu: a 0% APR short-term plan, a longer plan with interest, perhaps a 12-month option. The patient picks one. The patient e-signs. The provider, importantly, gets paid upfront - usually within a day or two - regardless of whether the patient eventually defaults.

Cherry is, technically, not a bank. The originating bank partner is Cross River. Cherry is the platform - the underwriting, the UX, the merchant integration, the collections, and increasingly the capital-markets engineering. The revenue model is two-sided: a merchant fee on each financed transaction, and interest on the longer-tenor loans. It is, as fintech business models go, refreshingly honest about how it makes money.

04The proof

Fig. 2 - Cherry does not publish vertical splits. These are reasonable approximations from public press and competitive disclosures. Take with a grain of fluoride.

By 2022 Cherry had raised roughly $80M in equity across seed, Series A, and a $44M Series B led by DCM and Kleiner Perkins. Cross River had extended a $50M strategic credit facility the same year. By 2024 the total - debt and equity - was reported at around $213M. The company was, by one trade-press account, exploring asset-backed bonds tied specifically to cosmetic-surgery BNPL loans. The phrase "Botox-backed securities" was not used by Cherry. It was used by approximately everyone else.

Fig. 3 - Six years from pitch deck to default category leader. Compiled from Crunchbase, PitchBook, BusinessWire and Cherry's own disclosures.

05The mission

Cherry's stated mission is, by fintech standards, refreshingly free of moonshot language. "Help health and wellness providers serve more people with convenient and cost-effective buy-now-pay-later." There is no talk of reinventing money. There is no white paper. There is, instead, a list of four internal values that read like the inside of a Stripe handbook crossed with a dental school orientation pamphlet: Provider Obsession, Be An Owner, Seek Truth Through Facts, Celebrate Excellence.

Critics of healthcare BNPL - and they exist, loudly - will argue that financing elective procedures is a polite way of selling debt to people who already have too much of it. Cherry's counter is that the alternative for most patients is not "less care." It is "the same procedure, later, on a credit card at 27%, after another year of putting it off." That is a defensible position. It is also one the company will need to keep defending, and the consumer-finance regulators will keep asking.

06Why it matters tomorrow

Three things make Cherry interesting beyond the dental chair. First: it is one of the very few vertical BNPL companies that has not been crushed by Affirm or Klarna. The healthcare distribution is too fiddly, the merchant integration too specific, and Cherry got there first. Second: the credit performance of healthcare-financed loans has historically been more stable than general retail BNPL. People skip a sweater payment. They are less likely to skip a payment on their mother's hip surgery. Third: as the company moves into capital markets and securitization, it will turn its loan book into a fee-generating asset class - which is exactly what its competitors at Affirm have been doing, only quieter, and on top of a less generic merchant network.

None of that is guaranteed. Consumer-credit regulation is tightening. Sunbit and CareCredit are both very much still here. A recession would hit elective procedures faster than dental emergencies. Cherry's bet remains that the office manager in Tulsa would rather work with one familiar tablet than juggle three financing vendors and a payment terminal - and on that point, the office manager appears, so far, to agree.

Return to the waiting room. The patient with the $6,400 estimate has finished her consult. Five years ago she would have been handed a CareCredit brochure, a pen, and a phone number. Three years ago she might have been told to come back when she had saved up. Today she scans a QR code, waits less time than it takes the hygienist to switch trays, and books the appointment for next Tuesday. The crowns will be done by month-end. The dentist's accounts receivable balance, for this case, will be zero. The patient will pay Cherry in twelve installments. Nobody at the cocktail party will know it happened. Which is, possibly, the point.